IGF2: Epigenetic regulation and role in development and disease

Cytokine and Growth Factor Reviews

Volumn 19, Issue 2, 2008, Pages 111-120

  Chao, Wendy ^a   D'Amore, Patricia A ^a  

^a SCHEPENS EYE RESEARCH INSTITUTE   (United States)

Author keywords

Angiogenesis; Imprinting; Insulin like growth factor; Sonic hedgehog; Vascular endothelial growth factor

Indexed keywords

SOMATOMEDIN B; SOMATOMEDIN BINDING PROTEIN; SONIC HEDGEHOG PROTEIN; VASCULOTROPIN;

ACCURACY; ALLELE; ANGIOGENESIS; CELL DIFFERENTIATION; CELL GROWTH; EPIGENETICS; GENE CONTROL; GENE DISRUPTION; GENE EXPRESSION; GENE OVEREXPRESSION; GENE REPRESSION; GENOME IMPRINTING; GROWTH CURVE; MEDULLOBLASTOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN FUNCTION; REVIEW; RHABDOMYOSARCOMA; SIGNAL TRANSDUCTION;

ALLELES; ANIMALS; BINDING SITES; CELL DIFFERENTIATION; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, DEVELOPMENTAL; GENOMIC IMPRINTING; HEDGEHOG PROTEINS; HUMANS; INSULIN-LIKE GROWTH FACTOR II; MODELS, BIOLOGICAL; NEOVASCULARIZATION, PATHOLOGIC; NEOVASCULARIZATION, PHYSIOLOGIC; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

ERINACEIDAE;

EID: 40749128979     PISSN: 13596101     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cytogfr.2008.01.005     Document Type: Review

References (100)

1. Carrel A. Artificial activation of the growth in vitro of connective tissue. J Exp Med 17 (1913) 14-19
2. Westwood M., Jabbour H., Bloom S., Whitehead S., Barber T., Chapman J., et al. Ten hot hormones. Endocrinologist 75 (2005) [Spring 2005, Feature]
3. Salmon Jr. W.D., and Daughaday W.H. A hormonally controlled serum factor which stimulates sulfate incorporation by cartilage in vitro. J Lab Clin Med 49 6 (1957) 825-836
4. Froesch E.R., Buergi H., Ramseier E.B., Bally P., and Labhart A. Antibody-suppressible and nonsuppressible insulin-like activities in human serum and their physiologic significance. an insulin assay with adipose tissue of increased precision and specificity. J Clin Invest 42 (1963) 1816-1834
5. Daughaday W.H., Hall K., Raben M.S., Salmon Jr. W.D., van den Brande J.L., and van Wyk J.J. Somatomedin: proposed designation for sulphation factor. Nature 235 5333 (1972) 107
6. Dulak N.C., and Temin H.M. Multiplication-stimulating activity for chicken embryo fibroblasts from rat liver cell conditioned medium: a family of small polypeptides. J Cell Physiol 81 2 (1973) 161-170
7. Rinderknecht E., and Humbel R.E. Amino-terminal sequences of two polypeptides from human serum with nonsuppressible insulin-like and cell-growth-promoting activities: evidence for structural homology with insulin B chain. Proc Natl Acad Sci USA 73 12 (1976) 4379-4381
8. Marquardt H., Todaro G.J., Henderson L.E., and Oroszlan S. Purification and primary structure of a polypeptide with multiplication-stimulating activity from rat liver cell cultures. Homology with human insulin-like growth factor II. J Biol Chem 256 13 (1981) 6859-6865
9. Daughaday W.H., Hall K., Salmon Jr. W.D., Van den Brande J.L., and Van Wyk J.J. On the nomenclature of the somatomedins and insulin-like growth factors. Endocrinology 121 5 (1987) 1911-1912
10. Zhou Y., Xu B.C., Maheshwari H.G., He L., Reed M., Lozykowski M., et al. A mammalian model for Laron syndrome produced by targeted disruption of the mouse growth hormone receptor/binding protein gene (the Laron mouse). Proc Natl Acad Sci USA 94 24 (1997) 13215-13220
11. Denley A., Wang C.C., McNeil K.A., Walenkamp M.J., van Duyvenvoorde H., Wit J.M., et al. Structural and functional characteristics of the Val44Met insulin-like growth factor I missense mutation: correlation with effects on growth and development. Mol Endocrinol (Baltimore, MD) 19 3 (2005) 711-721
12. Powell-Braxton L., Hollingshead P., Warburton C., Dowd M., Pitts-Meek S., Dalton D., et al. IGF-I is required for normal embryonic growth in mice. Genes Dev 7 12B (1993) 2609-2617
13. Baker J., Liu J.P., Robertson E.J., and Efstratiadis A. Role of insulin-like growth factors in embryonic and postnatal growth. Cell 75 1 (1993) 73-82
14. DeChiara T.M., Robertson E.J., and Efstratiadis A. Parental imprinting of the mouse insulin-like growth factor II gene. Cell 64 4 (1991) 849-859
15. LeRoith D., and Roberts Jr. C.T. The insulin-like growth factor system and cancer. Cancer Lett 195 2 (2003) 127-137
16. Reik W., Constancia M., Dean W., Davies K., Bowden L., Murrell A., et al. Igf2 imprinting in development and disease. Int J Dev Biol 44 1 (2000) 145-150
17. Clemmons D.R. Insulin-like growth factor binding proteins and their role in controlling IGF actions. Cytokine Growth Factor Rev 8 1 (1997) 45-62
18. Constancia M., Hemberger M., Hughes J., Dean W., Ferguson-Smith A., Fundele R., et al. Placental-specific IGF-II is a major modulator of placental and fetal growth. Nature 417 6892 (2002) 945-948
19. Ohlsson R., Hedborg F., Holmgren L., Walsh C., and Ekstrom T.J. Overlapping patterns of IGF2 and H19 expression during human development: biallelic IGF2 expression correlates with a lack of H19 expression. Development (Cambridge, England) 120 2 (1994) 361-368
20. de Pagter-Holthuizen P., Jansen M., van Schaik F.M., van der Kammen R., Oosterwijk C., Van den Brande J.L., et al. The human insulin-like growth factor II gene contains two development-specific promoters. FEBS Lett 214 2 (1987) 259-264
21. Rotwein P., and Hall L.J. Evolution of insulin-like growth factor II: characterization of the mouse IGF-II gene and identification of two pseudo-exons. DNA Cell Biol 9 10 (1990) 725-735
22. Lewis A., and Reik W. How imprinting centres work. Cytogenet Genome Res 113 1-4 (2006) 81-89
23. Thorvaldsen J.L., Duran K.L., and Bartolomei M.S. Deletion of the H19 differentially methylated domain results in loss of imprinted expression of H19 and Igf2. Genes Dev 12 23 (1998) 3693-3702
24. Ohlsson R., Renkawitz R., and Lobanenkov V. CTCF is a uniquely versatile transcription regulator linked to epigenetics and disease. Trends Genet 17 9 (2001) 520-527
25. Bell A.C., and Felsenfeld G. Methylation of a CTCF-dependent boundary controls imprinted expression of the Igf2 gene. Nature 405 6785 (2000) 482-485
26. Chao W., Huynh K.D., Spencer R.J., Davidow L.S., and Lee J.T. CTCF, a candidate trans-acting factor for X-inactivation choice. Science (New York, NY) 295 5553 (2002) 345-347
27. Boumil R.M., Ogawa Y., Sun B.K., Huynh K.D., and Lee J.T. Differential methylation of Xite and CTCF sites in Tsix mirrors the pattern of X-inactivation choice in mice. Mol Cell Biol 26 6 (2006) 2109-2117
28. Stavropoulos N., Rowntree R.K., and Lee J.T. Identification of developmentally specific enhancers for Tsix in the regulation of X chromosome inactivation. Mol Cell Biol 25 7 (2005) 2757-2769
29. Lyon M.F. Gene action in the X-chromosome of the mouse (Mus musculus L.). Nature 190 (1961) 372-373
30. Thorvaldsen J.L., Verona R.I., and Bartolomei M.S. X-tra! X-tra! News from the mouse X chromosome. Dev Biol 298 2 (2006) 344-353
31. Lee J.T., Davidow L.S., Warshawsky D., and Tsix. a gene antisense to Xist at the X-inactivation centre. Nat Genet 21 4 (1999) 400-404
32. Kim T.H., Abdullaev Z.K., Smith A.D., Ching K.A., Loukinov D.I., Green R.D., et al. Analysis of the vertebrate insulator protein CTCF-binding sites in the human genome. Cell 128 6 (2007) 1231-1245
33. Do Kim J., Hinz A.K., Ha Choo J., Stubbs L., and Kim J. YY1 as a controlling factor for the Peg3 and Gnas imprinted domains. Genomics 89 2 (2007) 262-269
34. Donohoe M.E., Zhang L.F., Xu N., Shi Y., and Lee J.T. Identification of a Ctcf cofactor, Yy1, for the X chromosome binary switch. Mol Cell 25 1 (2007) 43-56
35. Ling J.Q., Li T., Hu J.F., Vu T.H., Chen H.L., Qiu X.W., et al. CTCF mediates interchromosomal colocalization between Igf2/H19 and Wsb1/Nf1. Science (New York, NY) 312 5771 (2006) 269-272
36. Lupski J.R., and Stankiewicz P. Genomic disorders: molecular mechanisms for rearrangements and conveyed phenotypes. PLoS Genet 1 6 (2005) e49
37. Medema R.H., and Burgering B.M. The X Factor: skewing X Inactivation towards Cancer. Cell 129 7 (2007) 1253-1254
38. Zuo T., Wang L., Morrison C., Chang X., Zhang H., Li W., et al. FOXP3 is an X-linked breast cancer suppressor gene and an important repressor of the HER-2/ErbB2 oncogene. Cell 129 7 (2007) 1275-1286
39. Foulstone E., Prince S., Zaccheo O., Burns J.L., Harper J., Jacobs C., et al. Insulin-like growth factor ligands, receptors, and binding proteins in cancer. J Pathol 205 2 (2005) 145-153
40. Rivera M.N., Kim W.J., Wells J., Driscoll D.R., Brannigan B.W., Han M., et al. An X chromosome gene, WTX, is commonly inactivated in Wilms tumor. Science (New York, NY) 315 5812 (2007) 642-645
41. Moore T., Constancia M., Zubair M., Bailleul B., Feil R., Sasaki H., et al. Multiple imprinted sense and antisense transcripts, differential methylation and tandem repeats in a putative imprinting control region upstream of mouse Igf2. Proc Natl Acad Sci USA 94 23 (1997) 12509-12514
42. Okutsu T., Kuroiwa Y., Kagitani F., Kai M., Aisaka K., Tsutsumi O., et al. Expression and imprinting status of human PEG8/IGF2AS, a paternally expressed antisense transcript from the IGF2 locus, in Wilms' tumors. J Biochem (Tokyo) 127 3 (2000) 475-483
43. Vu T.H., Chuyen N.V., Li T., and Hoffman A.R. Loss of imprinting of IGF2 sense and antisense transcripts in Wilms' tumor. Cancer Res 63 8 (2003) 1900-1905
44. Denley A., Wallace J.C., Cosgrove L.J., and Forbes B.E. The insulin receptor isoform exon 11- (IR-A) in cancer and other diseases: a review. Horm Metab Res Horm Stoffwechselforschung 35 11-12 (2003) 778-785
45. Denley A., Bonython E.R., Booker G.W., Cosgrove L.J., Forbes B.E., Ward C.W., et al. Structural determinants for high-affinity binding of insulin-like growth factor II to insulin receptor (IR)-A, the exon 11 minus isoform of the IR. Mol Endocrinol (Baltimore, MD) 18 10 (2004) 2502-2512
46. White M.F. Regulating insulin signaling and beta-cell function through IRS proteins. Can J Physiol Pharmacol 84 7 (2006) 725-737
47. Denley A., Cosgrove L.J., Booker G.W., Wallace J.C., and Forbes B.E. Molecular interactions of the IGF system. Cytokine Growth Factor Rev 16 4-5 (2005) 421-439
48. Scott C.D., and Firth S.M. The role of the M6P/IGF-II receptor in cancer: tumor suppression or garbage disposal?. Horm Metab Res Horm Stoffwechselforschung 36 5 (2004) 261-271
49. Petley T., Graff K., Jiang W., Yang H., and Florini J. Variation among cell types in the signaling pathways by which IGF-I stimulates specific cellular responses. Horm Metab Res Horm Stoffwechselforschung 31 2-3 (1999) 70-76
50. Baserga R., Peruzzi F., and Reiss K. The IGF-1 receptor in cancer biology. Int J Cancer 107 6 (2003) 873-877
51. Hennessy B.T., Smith D.L., Ram P.T., Lu Y., and Mills G.B. Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov 4 12 (2005) 988-1004
52. Wilson E.M., Hsieh M.M., and Rotwein P. Autocrine growth factor signaling by insulin-like growth factor-II mediates MyoD-stimulated myocyte maturation. J Biol Chem 278 42 (2003) 41109-41113
53. Wilson E.M., and Rotwein P. Control of MyoD function during initiation of muscle differentiation by an autocrine signaling pathway activated by insulin-like growth factor-II. J Biol Chem 281 40 (2006) 29962-29971
54. Minuto F., Palermo C., Arvigo M., and Barreca A.M. The IGF system and bone. J Endocrinol Invest 28 Suppl. 8 (2005) 8-10
55. Wang Z.Q., Fung M.R., Barlow D.P., and Wagner E.F. Regulation of embryonic growth and lysosomal targeting by the imprinted Igf2/Mpr gene. Nature 372 6505 (1994) 464-467
56. Leighton P.A., Ingram R.S., Eggenschwiler J., Efstratiadis A., and Tilghman S.M. Disruption of imprinting caused by deletion of the H19 gene region in mice. Nature 375 6526 (1995) 34-39
57. Sun F.L., Dean W.L., Kelsey G., Allen N.D., and Reik W. Transactivation of Igf2 in a mouse model of Beckwith-Wiedemann syndrome. Nature 389 6653 (1997) 809-815
58. Morison I.M., and Reeve A.E. Insulin-like growth factor 2 and overgrowth: molecular biology and clinical implications. Mol Med Today 4 3 (1998) 110-115
59. Sparago A., Cerrato F., Vernucci M., Ferrero G.B., Silengo M.C., and Riccio A. Microdeletions in the human H19 DMR result in loss of IGF2 imprinting and Beckwith-Wiedemann syndrome. Nat Genet 36 9 (2004) 958-960
60. Prawitt D., Enklaar T., Gartner-Rupprecht B., Spangenberg C., Oswald M., Lausch E., et al. Microdeletion of target sites for insulator protein CTCF in a chromosome 11p15 imprinting center in Beckwith-Wiedemann syndrome and Wilms' tumor. Proc Natl Acad Sci USA 102 11 (2005) 4085-4090
61. Feinberg A.P., Ohlsson R., and Henikoff S. The epigenetic progenitor origin of human cancer. Nat Rev 7 1 (2006) 21-33
62. Bae S.K., Bae M.H., Ahn M.Y., Son M.J., Lee Y.M., Bae M.K., et al. Egr-1 mediates transcriptional activation of IGF-II gene in response to hypoxia. Cancer Res 59 23 (1999) 5989-5994
63. Ravenel J.D., Broman K.W., Perlman E.J., Niemitz E.L., Jayawardena T.M., Bell D.W., et al. Loss of imprinting of insulin-like growth factor-II (IGF2) gene in distinguishing specific biologic subtypes of Wilms tumor. J Natl Cancer Inst 93 22 (2001) 1698-1703
64. McCann A.H., Miller N., O'Meara A., Pedersen I., Keogh K., Gorey T., et al. Biallelic expression of the IGF2 gene in human breast disease. Hum Mol Genet 5 8 (1996) 1123-1127
65. Kaneda A., and Feinberg A.P. Loss of imprinting of IGF2: a common epigenetic modifier of intestinal tumor risk. Cancer Res 65 24 (2005) 11236-11240
66. Docquier F., Farrar D., D'Arcy V., Chernukhin I., Robinson A.F., Loukinov D., et al. Heightened expression of CTCF in breast cancer cells is associated with resistance to apoptosis. Cancer Res 65 12 (2005) 5112-5122
67. Hong J.A., Kang Y., Abdullaev Z., Flanagan P.T., Pack S.D., Fischette M.R., et al. Reciprocal binding of CTCF and BORIS to the NY-ESO-1 promoter coincides with derepression of this cancer-testis gene in lung cancer cells. Cancer Res 65 17 (2005) 7763-7774
68. Vatolin S., Abdullaev Z., Pack S.D., Flanagan P.T., Custer M., Loukinov D.I., et al. Conditional expression of the CTCF-paralogous transcriptional factor BORIS in normal cells results in demethylation and derepression of MAGE-A1 and reactivation of other cancer-testis genes. Cancer Res 65 17 (2005) 7751-7762
69. Ulaner G.A., Vu T.H., Li T., Hu J.F., Yao X.M., Yang Y., et al. Loss of imprinting of IGF2 and H19 in osteosarcoma is accompanied by reciprocal methylation changes of a CTCF-binding site. Hum Mol Genet 12 5 (2003) 535-549
70. Jelinic P., and Shaw P. Loss of imprinting and cancer. J Pathol 211 3 (2007) 261-268
71. Ruiz i Altaba A., Sanchez P., and Dahmane N. Gli and hedgehog in cancer: tumours, embryos and stem cells. Nat Rev Cancer 2 5 (2002) 361-372
72. Ingram W.J., Wicking C.A., Grimmond S.M., Forrest A.R., and Wainwright B.J. Novel genes regulated by Sonic Hedgehog in pluripotent mesenchymal cells. Oncogene 21 53 (2002) 8196-8205
73. Hahn H., Wojnowski L., Specht K., Kappler R., Calzada-Wack J., Potter D., et al. Patched target Igf2 is indispensable for the formation of medulloblastoma and rhabdomyosarcoma. J Biol Chem 275 37 (2000) 28341-28344
74. Yoon J.W., Kita Y., Frank D.J., Majewski R.R., Konicek B.A., Nobrega M.A., et al. Gene expression profiling leads to identification of GLI1-binding elements in target genes and a role for multiple downstream pathways in GLI1-induced cell transformation. J Biol Chem 277 7 (2002) 5548-5555
75. Firth S.M., and Baxter R.C. Cellular actions of the insulin-like growth factor binding proteins. Endocr Rev 23 6 (2002) 824-854
76. Bates P., Fisher R., Ward A., Richardson L., Hill D.J., and Graham C.F. Mammary cancer in transgenic mice expressing insulin-like growth factor II (IGF-II). Br J Cancer 72 5 (1995) 1189-1193
77. Rao G., Pedone C.A., Valle L.D., Reiss K., Holland E.C., and Fults D.W. Sonic hedgehog and insulin-like growth factor signaling synergize to induce medulloblastoma formation from nestin-expressing neural progenitors in mice. Oncogene 23 36 (2004) 6156-6162
78. Christofori G., Naik P., and Hanahan D. A second signal supplied by insulin-like growth factor II in oncogene-induced tumorigenesis. Nature 369 6479 (1994) 414-418
79. Sivridis E., Giatromanolaki A., and Koukourakis M.I. The vascular network of tumours-what is it not for?. J Pathol 201 2 (2003) 173-180
80. 2 homeostasis by hypoxia-inducible factor 1. Annu Rev Cell Dev Biol 15 (1999) 551-578
81. Dvorak H.F. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol 20 21 (2002) 4368-4380
82. Shima D.T., Deutsch U., and D'Amore P.A. Hypoxic induction of vascular endothelial growth factor (VEGF) in human epithelial cells is mediated by increases in mRNA stability. FEBS Lett 370 3 (1995) 203-208
83. Loureiro R.M., and D'Amore P.A. Transcriptional regulation of vascular endothelial growth factor in cancer. Cytokine Growth Factor Rev 16 1 (2005) 77-89
84. Kim K.W., Bae S.K., Lee O.H., Bae M.H., Lee M.J., and Park B.C. Insulin-like growth factor II induced by hypoxia may contribute to angiogenesis of human hepatocellular carcinoma. Cancer Res 58 2 (1998) 348-351
85. Kwon Y.W., Kwon K.S., Moon H.E., Park J.A., Choi K.S., Kim Y.S., et al. Insulin-like growth factor-II regulates the expression of vascular endothelial growth factor by the human keratinocyte cell line HaCaT. J Invest Dermatol 123 1 (2004) 152-158
86. Kim H.J., and Kim T.Y. Regulation of vascular endothelial growth factor expression by insulin-like growth factor-II in human keratinocytes, differential involvement of mitogen-activated protein kinases and feedback inhibition of protein kinase C. Br J Dermatol 152 3 (2005) 418-425
87. Feldser D., Agani F., Iyer N.V., Pak B., Ferreira G., and Semenza G.L. Reciprocal positive regulation of hypoxia-inducible factor 1alpha and insulin-like growth factor 2. Cancer Res 59 16 (1999) 3915-3918
88. Chen J., and Smith L.E. Retinopathy of prematurity. Angiogenesis 10 2 (2007) 133-140
89. Guidry C., Feist R., Morris R., and Hardwick C.W. Changes in IGF activities in human diabetic vitreous. Diabetes 53 9 (2004) 2428-2435
90. Lofqvist C., Chen J., Connor K.M., Smith A.C., Aderman C.M., Liu N., et al. From the Cover: IGFBP3 suppresses retinopathy through suppression of oxygen-induced vessel loss and promotion of vascular regrowth. Proc Natl Acad Sci USA 104 25 (2007) 10589-10594
91. Chen J.N., Haffter P., Odenthal J., Vogelsang E., Brand M., van Eeden F.J., et al. Mutations affecting the cardiovascular system and other internal organs in zebrafish. Development (Cambridge, England) 123 (1996) 293-302
92. Brown L.A., Rodaway A.R., Schilling T.F., Jowett T., Ingham P.W., Patient R.K., et al. Insights into early vasculogenesis revealed by expression of the ETS-domain transcription factor Fli-1 in wild-type and mutant zebrafish embryos. Mech Dev 90 2 (2000) 237-252
93. Lawson N.D., Vogel A.M., and Weinstein B.M. Sonic hedgehog and vascular endothelial growth factor act upstream of the Notch pathway during arterial endothelial differentiation. Dev Cell 3 1 (2002) 127-136
94. Dyer M.A., Farrington S.M., Mohn D., Munday J.R., and Baron M.H. Indian hedgehog activates hematopoiesis and vasculogenesis and can respecify prospective neurectodermal cell fate in the mouse embryo. Development (Cambridge, England) 128 10 (2001) 1717-1730
95. Byrd N., Becker S., Maye P., Narasimhaiah R., St-Jacques B., Zhang X., et al. Hedgehog is required for murine yolk sac angiogenesis. Development (Cambridge, England) 129 2 (2002) 361-372
96. Pepicelli C.V., Lewis P.M., and McMahon A.P. Sonic hedgehog regulates branching morphogenesis in the mammalian lung. Curr Biol 8 19 (1998) 1083-1086
97. Rowitch D.H., St.-Jacques B., Lee S.M., Flax J.D., Snyder E.Y., and McMahon A.P. Sonic hedgehog regulates proliferation and inhibits differentiation of CNS precursor cells. J Neurosci 19 October (20) (1999) 8954-8965
98. Pola R., Ling L.E., Silver M., Corbley M.J., Kearney M., Blake Pepinsky R., et al. The morphogen Sonic hedgehog is an indirect angiogenic agent upregulating two families of angiogenic growth factors. Nat Med 7 6 (2001) 706-711
99. Ruiz i Altaba A. Gli proteins encode context-dependent positive and negative functions: implications for development and disease. Development (Cambridge, England) 126 14 (1999) 3205-3216
100. Sasaki H., Nishizaki Y., Hui C., Nakafuku M., and Kondoh H. Regulation of Gli2 and Gli3 activities by an amino-terminal repression domain: implication of Gli2 and Gli3 as primary mediators of Shh signaling. Development (Cambridge, England) 126 17 (1999) 3915-3924